Related Experiment Video

Updated: Jun 7, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

The role of MELK in cancer and its interactions with non-coding RNAs: Implications for therapeutic strategies

Dong Oh Moon1

  • 1Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si, 38453 Gyeongsangbuk-do, Republic of Korea.

Bulletin Du Cancer
|November 19, 2024
PubMed

Insights

Maternal Embryonic Leucine Zipper Kinase (MELK) and non-coding RNAs (ncRNAs) are key in cancer. Understanding their interactions offers new therapeutic strategies to combat cancer progression and treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Maternal Embryonic Leucine Zipper Kinase (MELK) is a critical regulator of cancer cell proliferation, survival, and therapy evasion.
  • Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), significantly modulate gene expression and cancer phenotypes.
  • The interplay between MELK and ncRNAs in cancer is increasingly recognized as a crucial area of investigation.

Purpose of the Study:

  • To explore the interactions between MELK and ncRNAs in cancer biology.
  • To identify novel therapeutic targets by investigating MELK-ncRNA crosstalk.
  • To enhance the understanding of molecular underpinnings of cancer progression and treatment resistance.

Main Methods:

  • This study focuses on investigating the crosstalk between MELK and various ncRNAs.
  • Potential methods include molecular biology techniques, genetic analysis, and functional assays to elucidate these interactions.
  • Further research will likely involve in vitro and in vivo models to validate findings.

Main Results:

  • Early investigations suggest a significant role for MELK-ncRNA interactions in cancer development.
  • Disruption of these interactions holds potential for therapeutic intervention.
  • This research opens avenues for novel targeted cancer therapies.

Conclusions:

  • MELK and ncRNAs are pivotal in cancer biology, and their crosstalk represents a promising frontier for therapeutic innovation.
  • Targeting MELK-ncRNA interactions could offer a novel strategy to counteract cancer progression.
  • Further research into this crosstalk is essential for developing improved cancer treatments.
Keywords:
MELKlncRNAmiRNAncRNA

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

147
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K